摘要
Abstract
Objective:To evaluate the cost-utility of three bismuth-containing quadruple regimens for Helicobacter Pylori(Hp)eradi-cation in China:Tegoprazan-based,Esomeprazole-based,and Vonoprazan-based regimens.Methods:A Markov model was developed to conduct a cost-utility analysis from the perspective of China's healthcare system,with a lifetime horizon.The main outcomes included in-cremental cost,incremental quality-adjusted life years(QALYs),and incremental cost-utility ratios(ICUR).One-way sensitivity analysis and probabilistic sensitivity analysis were performed to validate the results.Results:Compared with the Esomeprazole group,the Tego-prazan group yielded an additional 0.017 QALYs and an additional cost of 223 RMB,resulting in an ICUR of 13 442 RMB/QALY,which is approximately 0.14 times the GDP per capita in 2024,indicating a clear cost-utility advantage.Compared with the Vonoprazan group,the Tegoprazan group provided an additional 0.016 QALYs and reduced costs by 78 RMB,resulting in an ICUR of-4 855 RMB/QALY,establishing it as the dominant option.Using a thresholding of one to three 2024 GDP per capita(95 749 RMB to 287 247 RMB)for cost-utility evaluation,the probabilistic sensitivity analysis demonstrated a nearly 100％acceptability rate for the Tegoprazan group compared to both the Esomeprazole and Vonoprazan groups within the range of threshold from 0 to 287,247 RMB,confirming the robustness of its cost-utility.Further analysis using the efficiency frontier approach confirms that within the threshold range of this study,the Tegoprazan group is a more cost-effective choice.Conclusion:The Tegoprazan-based regimen is more cost-effective than both the Esomeprazole-based regi-men and the Vonoprazan-based regimen for Hp eradication in China.关键词
替戈拉生/幽门螺杆菌感染/成本-效用分析/Markov模型Key words
Tegoprazan/Helicobacter Pylori/Cost utility analysis/Markov model分类
医药卫生
